Foghorn Therapeutics (FHTX) FCF Margin (2020 - 2026)

Foghorn Therapeutics' FCF Margin history runs 7 years deep, the most recent figure standing at 774.44% for Q1 2026.

• In Q1 2026, FCF Margin fell 37128.0% year-over-year to 774.44%; the TTM figure through Mar 2026 stood at 309.86% (up 9800.0% YoY), while the FY2025 annual figure was 278.72%, up 16953.0% from the prior year.
• FCF Margin was 774.44% for Q1 2026 at Foghorn Therapeutics, down from 241.39% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 6920.59% in Q1 2022 to a low of 880.11% in Q4 2024.
• Historically, FCF Margin has averaged 32.43% across 5 years, with a median of 403.16% in 2025.
• The sharpest annual moves came in 2022 and 2023: FCF Margin surged 5025357 bps in 2022, then sank 751350 bps in 2023.
• A 5-year view of FCF Margin shows it stood at 697.73% in 2022, then soared by 34 bps to 457.43% in 2023, then tumbled by 92 bps to 880.11% in 2024, then surged by 73 bps to 241.39% in 2025, then plunged by 221 bps to 774.44% in 2026.
• The last three FCF Margin figures came in at 774.44% (Q1 2026), 241.39% (Q4 2025), and 230.71% (Q3 2025), per Business Quant data.